Abstract: Various embodiments of a device for in-vivo measurements radiopharmaceuticals used for diagnosis and monitoring of radiotherapy are presented. In some embodiments, the present disclosure relates to a device having a cannula that may include a measurement chamber, a radiation detector and a delivery lumen, wherein the device may be used to both deliver material to the patient (e.g., radiotracers used in radiopharmaceuticals) and measure levels and concentrations of radioactive material in, for example, the patient's blood both during and after administration of the radioactive material. In some embodiments, particles emitted by the radioactive material interact with a scintillation material, resulting in the release of light that may be transmitted, via the scintillation material and/or fiber optic material, to an optical detectors or processor for processing.

Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).

Abstract: Methods and therapeutic compositions are disclosed for treating neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and/or Huntington's disease, using Salubrinal analogs, or pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: A system and method for determining accumulated radiation dose is presented. In some embodiments, the system and method include use of one or more RADFETs to measure and accumulated radiation dose over a desired period of time from an area of interest in a patient. In some embodiments, the one or more RADFETs may be arranged on a test strip, and electrical circuitry provided to selectively couple certain terminals of the RADFETS together to facilitate improved measurement of accumulated dose. A reader may also be utilized wherein the reader may receive a test strip, decouple the electrical connections between select terminals, inject a current into the RADFET and/or measure a voltage from the RADFET corresponding to an accumulated radiation dose.

Abstract: Methods and therapeutic compositions are disclosed for treating neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and/or Huntington's disease, using Salubrinal analogs, or pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).

Abstract: Various embodiments of a device for in-vivo measurements radiopharmaceuticals used for diagnosis and monitoring of radiotherapy are presented. In some embodiments, the present disclosure relates to a device having a cannula that may include a measurement chamber, a radiation detector and a delivery lumen, wherein the device may be used to both deliver material to the patient (e.g., radiotracers used in radiopharmaceuticals) and measure levels and concentrations of radioactive material in, for example, the patient's blood both during and after administration of the radioactive material. In some embodiments, particles emitted by the radioactive material interact with a scintillation material, resulting in the release of light that may be transmitted, via the scintillation material and/or fiber optic material, to an optical detectors or processor for processing.

Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).

Abstract: A system and method for the measurement of radiation emitted from the body, for example, is presented. In one example, radiation sensors (e.g., gamma radiation sensors) may be used to measure activity proximate an injection site as a function of time. In some embodiments, one or more rangefinders may be employed to determine a size and/or position of a subject relative to the radiation sensors to better account for varying material densities within the system in estimating, for example, the amount of radioactive material in the tissue proximate the injection site. With an estimated function of radioactive material proximate the injection site as a function of time known, an estimated arterial input function may be determined, allowing for calculation of a correction factor that may be applied by a clinician during nuclear medical imaging. The magnitude, location, and volume of the radioactive source in the body may also be estimated.

Abstract: Methods and therapeutic compositions are disclosed for treating neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease and/or Huntington's disease, using Salubrinal analogs, or pharmaceutically acceptable salts, hydrates, or solvates thereof.

Abstract: A system and method for the measurement of radiation emitted from the body, for example, is presented. In one example, radiation sensors (e.g., gamma radiation sensors) may be used to measure activity proximate an injection site as a function of time. With that data, a function describing an amount of radioactive material in tissue proximate the injection site as a function of time may be estimated where an amount of radioactive material in the tissue at a time t is known. When an array of sensors is employed, the amount of radioactive material in the tissue proximate the injection site may be determined directly by the system. With an estimated function of radioactive material proximate the injection site as a function of time known, an estimated arterial input function may be determined, allowing for calculation of a correction factor that may be applied by a clinician during nuclear medical imaging.

Abstract: Various embodiments of a device for in-vivo measurements radiopharmaceuticals used for diagnosis and radiotherapy is presented. In some embodiments, the present disclosure relates to a scintillation device having a cannula that may include scintillation material and a delivery lumen, wherein the device may be used to both deliver material to the patient (e.g., deliver radiotracers used in radiopharmaceuticals) and measure levels of radioactive material in, for example, the patient's blood both during and after administration of the radioactive material. In some embodiments, particles emitted by the radioactive material interact with the scintillation material, resulting in the release of light that may be transmitted, via the scintillation material and/or fiber optic material, to one or more optical detectors or processors for processing.

Abstract: Methods and systems are disclosed for evaluating a neurological condition by employing at least one motion sensor, configured to be attached to a body appendage, a memory associated with the sensor(s) to periodically record movement data during periods of prescribed exercises; and a processor for analyzing changes in movement data over time to evaluate the progression of the neurological condition. In one embodiment, the neurological condition is ALS and at least four motion sensors are employed such that each arm and leg of the patient has an associated sensor. The sensors can be accelerometers that measure the displacement, velocity and acceleration of an associated limb during periods of prescribed exercise. For example, changes in the patient's ability to repeat a series of limb-lifting exercises or the measurement of limb tremors associated with the conduct of the exercises can be correlated with norms and analyzed to classify the stage of ALS in a patient and/or predict the rate of progression.

Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia.

Abstract: Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Abstract: Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells.

Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.

Abstract: Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells.

Abstract: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.